Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from CANbridge Pharmaceuticals Inc. ( (HK:1228) ) is now available.
CANbridge Pharmaceuticals Inc. announced an extraordinary general meeting (EGM) to be held virtually on December 4, 2025. The meeting will address resolutions including the revocation of the existing general mandate for issuing shares and the approval of a new mandate allowing directors to issue additional shares up to 20% of the total shares in issue. This strategic move is aimed at enhancing the company’s flexibility in capital management and potentially strengthening its market position.
The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of therapies for rare diseases and targeted cancers.
Average Trading Volume: 5,336,245
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.06B
See more insights into 1228 stock on TipRanks’ Stock Analysis page.